The historical rank and industry rank for GENinCode's EV-to-EBIT or its related term are showing as below:
LSE:GENI'
s EV-to-EBIT Range Over the Past 10 Years
Min: -39.61 Med: -0.33 Max: 2.57
Current: -1.42
During the past 5 years, the highest EV-to-EBIT of GENinCode was 2.57. The lowest was -39.61. And the median was -0.33.
LSE:GENI's EV-to-EBIT is ranked worse than 100% of 101
companies
in the Medical Diagnostics & Research industry
Industry Median: 20.28
vs LSE:GENI: -1.42
The historical data trend for GENinCode's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, GENinCode's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GENinCode's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GENinCode's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where GENinCode's EV-to-EBIT falls into.
GENinCode EV-to-EBIT Calculation
GENinCode's EV-to-EBIT for today is calculated as:
GENinCode's current Enterprise Value is £9.94 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. GENinCode's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-6.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GENinCode (LSE:GENI) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
GENinCode's Enterprise Value for the quarter that ended in Dec. 2023 was £2.80 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. GENinCode's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-6.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GENinCode EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of GENinCode's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment being sale of kits and provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain and United Kingdom.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:GENI has been successfully added to your